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Abstract 
Transforming growth factor  (TGF) family members are involved in a wide range of diverse 
functions and play key roles in embryogenesis, development and tissue homeostasis. Per-
turbation of TGF signaling may lead to vascular and other diseases. In vitro studies have 
provided evidence that TGF family members have a wide range of diverse effects on vascular 
cells, which are highly dependent on cellular context. Consistent with these observations 
genetic studies in mice and humans showed that TGF family members have ambiguous ef-
fects on the function of the cardiovascular system. In this review we discuss the recent ad-
vances on TGF signaling in (cardio)vascular diseases, and describe the value of TGF signaling 
as both a disease marker and therapeutic target for (cardio)vascular diseases. 
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Introduction 
Transforming  growth  factor    (TGF)  is  the 
prototype member of a highly evolutionary conserved 
secreted family of cytokines. The TGF family consists 
of  TGF,  activins,  inhibins,  nodals,  anti-mullerian 
hormone  (AMH)  and  bone  morphogenetic  proteins 
(BMPs)  [1,  2].  TGF  family  members  affect  various 
biological processes including cell proliferation, dif-
ferentiation,  migration,  adhesion,  apoptosis  and  ex-
tracellular  matrix  (ECM)  production.  Consequently 
TGF members play crucial role in embryonic devel-
opment, adult tissue homeostasis and in the patho-
genesis of a variety of diseases such as cancer, auto-
immune diseases, fibrosis and cardiovascular diseas-
es. They all exert their cellular effects via heteromeric 
complexes of type I and type II serine/threonine ki-
nase receptors located at the plasmamembrane, and 
the Smad transcription factors, which have a pivotal 
role in intracellular signaling [1, 3]. 
TGF family members act in a highly contextual 
manner and can either stimulate or inhibit angiogen-
esis. Genetic studies in mice and human have robustly 
confirmed the notion that TGF signaling is essential 
for  regulation  of  vasculogenesis  and  angiogenesis 
[3-6].  Inactivation  of  different  components  of  TGF 
signaling  in  mice  results  in  embryonic  lethality 
mainly due to defects in the vascular system. Likewise 
studies in human further corroborated the importance 
of TGF signaling in vascular function. Mutations in 
TGF  family  genes  or  mutations,  which  lead  to 
missregulated TGF signaling result in vascular pa-
thologies,  such  as  arteriovenous  malformations 
(AVMs),  aneurysms,  hypertension,  atherosclerosis 
and  cardiovascular  disease  [3,  4,  7].  Cardiovascular 
disease is by far the largest chronic health problem 
causing significant morbidity, mortality and despite 
the advances in preventive and therapeutic strategies, 
it remains the leading cause of death worldwide. 
Due to its role in the pathophysiology of cardi-
ovascular disease, TGF has been considered as a po-
tent therapeutic target in a wide spectrum of cardio-
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vascular  disorders.  However,  because  of  its  multi-
functional and context dependent action interference 
with  TGF-dependent  processes  must  be  carefully 
designed and the effects of TGF signaling or its in-
hibition on the different cell types involved must be 
carefully  studied.  Several  recent  reviews  have  dis-
cussed the role of TGF signaling in angiogenesis and 
tumor angiogenesis [4, 5, 8]. In the present review we 
will  focus  on  the  role  of  TGF  family  signaling  in 
(cardio)vascular diseases. 
TGF signaling 
TGF family proteins are generated as dimeric 
inactive precursor homodimers. The prototypic fam-
ily  member  TGF  is  secreted  as  an  inactive  latent 
precursor consisting of TGF and a latency associ-
ated peptide (LAP) [1, 2]. This complex is associated 
with the latent TGF binding proteins (LTBP). TGF 
gets  activated  by  proteolytic  cleavage  of  LAP  and 
LTBP by thrombospondin, plasmin, reactive oxygen 
species,  acidic  microenvironment,  matrix  metallo-
proteinases (MMP2 and 9) and 6 integrin [3]. Inter-
estingly  several  factors  involved  in  cardiovascular 
injury regulate TGF expression and activation. BMPs 
appear to be secreted in an active form; they are made 
in  the  cytoplasm  as  dimeric  pro-protein  complexes, 
which are cleaved by specific proteases. Once secreted 
their  bioavailability  is  regulated  through  reversible 
interactions  with  extracellular  antagonists  such  as 
Noggin, Chordin, Gremlin, cross-veinless 2 [CV2, also 
referred to as BMP endothelial cell precursor derived 
regulator (BMPER)] and matrix GLA protein (MGP). 
TGFβ family members elicit their cellular effects 
by inducing heterotetrameric complexes of type I and 
type  II  serine/threonine  kinase  transmembrane  re-
ceptors [1] (Fig. 1). A number of type I and II receptors 
have been identified. There are five type II receptors: 
activin receptor type IIA (ActRIIA), activin receptor 
type  IIB  (ActRIIB),  BMP  type  II  receptor  (BMPRII), 
TGF type II receptor (TRII) and AMH type II re-
ceptor  (AMHRII).  There  are  seven  type  I  receptors, 
termed activin receptor-like kinases (ALKs), ALK1- 7 
[1]. Different ligands can bind to different combina-
tions of type I and type II receptors resulting in signal 
specificity. TGFβ signals in most cells via TGFβ type II 
receptor (TβRII) and TβRI (ALK5); activins, inhibins 
and  nodal  signal  via  activin  receptor  type  IIA 
(ActRIIA) and IIB and ALK4; BMPs via BMP type II 
receptor (BMPRII), ActRIIs and ALK1, 2, 3 and 6 [1] 
(Fig. 1). 
Accessory  receptors  have  been  identified  that 
regulate access of TGF family members to signaling 
receptors. For TGF, endoglin and betaglycan, and the 
inhibitory  pseudoreceptor  BMP  and  activin  mem-
brane-bound inhibitor homolog (BAMBI) have been 
best characterized. TGF accessory receptors have a 
short intracellular domain that lacks catalytic activity. 
TGF2 can bind to TRII only in the presence of be-
taglycan. Endoglin expression enhances BMP signal-
ing, while has inhibitory effects on TGF/ALK5 sig-
naling [6]. Soluble forms of betaglycan and endoglin 
have been shown also to interfere with signaling by 
sequestering  TGF  family  ligands  from  binding  to 
signaling receptors. 
Ligand binding to the constitutively active type 
II receptor instigates the recruitment and phosphory-
lation  of  the  type  I  receptor  on  specific  serine  and 
threonine residues in its intracellular juxtamembrane 
region.  Upon  activation  type  I  receptor  recruits  the 
receptor regulated (R-)Smad proteins. Smads are in-
tracellular signal transducers for the TGF superfam-
ily and regulate transcription of target genes. Smad 
proteins are classified into three groups the R-Smad1, 
-2,  -3,  -5  and  -8,  common-mediator  Smads 
(Co-Smad4), and inhibitory Smads (I-Smad6 and -7) 
[1, 2] (Fig. 1). Activated type I receptors recruit and 
phosphorylate R-Smads at two serine residues in their 
extreme carboxyl termini. ALK4 and -5 (and -7) me-
diate R-Smad2 and -3 phosphorylation, while ALK1, 
-2, -3 and -6 mediate phosphorylation of R-Smad1, -5 
and -8. TGF, activins, inhibins, nodal signal usually 
through Smad2 and -3 [1, 2]. Studies on endothelial 
cells (ECs) revealed that TGF can signal through two 
distinct type receptors, i.e. ALK5 and the ALK1, re-
sulting  in  activation  of  both  Smad2/3  and 
Smad1/5/8, respectively [9]. Recently, it was demon-
strated that TGF can signal via the Smad1 pathway 
not only on ECs but also in tumor cells. BMPs and 
AMH  signal  through  Smad1,  -5  and  -8.  In  human 
pulmonary  artery  endothelial  cells  (PAECs)  BMP9 
was  shown  to  induce  phosphorylation  of  Smad1/5 
and Smad2 via BMPRII/ActRII/ALK1. While activa-
tion of both BMPR-II and ActRII  were required for 
Smad1  phosphorylation,  ActRII  mediated  a  greater 
proportion of phosphorylation on Smad2 [10]. 
Activated R-Smads interact with Smad4 and the 
tri- or dimeric formed complexes can translocate to 
the nucleus, where, together with other transcription 
factors, co-activators and co-repressors, they regulate 
target  gene  expression.  Inhibitory  (I)-  Smads,  i.e. 
Smad6  and  -7,  antagonize  signaling  by  inhibiting 
R-Smad activation either by competing with R-Smads 
for  type  I  receptor  interaction  and/or  by  recruiting 
specific ubiquitin ligases or phosphatases to the acti-
vated receptor complex, thereby targeting it for pro-
teosomal degradation or dephosphorylation, respec-
tively [1, 2, 11]. Additionally I-Smads can negatively Int. J. Biol. Sci. 2012, 8 
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regulate  TGF  family  signaling  via  degradation  of 
R-Smads  and  through  inhibition  of 
R-Smad-Co-Smad4 complex formation. Smad7 inhib-
its signaling from all branches of the TGF superfam-
ily, whereas Smad6 selectively inhibits BMP signaling 
[1, 2, 11]. 
Given  the  complexity  and  the  variety  of  the 
TGF  family  responses,  the  basic  Smad  signaling 
pathway  is  surprisingly  simple.  Besides  this  highly 
conserved signaling core, TGF ligands can regulate 
the activity of a number of other signaling pathways 
(non canonical pathways). TGF receptor activation 
results  in  activation  of  several  other  non-Smad  sig-
naling pathways in a context dependent manner (Fig. 
1). Non-Smad signaling pathways can involve activa-
tion of TGF activated kinase (TAK)-1, Extracellular 
signal-regulated  kinase  (ERK),  c-Jun  N-terminal  ki-
nase (JNK) and p38 mitogen activated protein (MAP) 
kinases,  Rho  GTPases,  PI3K-AKT  and  TRAF6  path-
way, which crosstalk with the Smad pathways [12]. In 
addition TGF signaling can be further regulated by 
different  signaling  cascades.  Classical  signaling  cas-
cades such as MAP kinases can influence the function 
and stability of Smad proteins through different types 
of modifications such as phosphorylation, ubiquitina-
tion and sumoylation [2]. Thus, cellular responses to 
TGF signaling result from the dynamic regulation of 
canonical and non-canonical cascades. 
TGF signaling and EC function 
Genetic studies in mice and humans have pro-
vided evidence for the importance of components of 
the TGF signaling pathway in vascular morphogen-
esis and angiogenesis. Deletion of components of the 
TGF  pathway  (ligands,  receptors  and  intracellular 
Smad mediators) in mice leads to embryonic lethality 
due to vascular abnormalities (Table 1) (reviewed in 
[3, 4, 7, 8]). 
 
 
Figure 1. Signal transduction by TGF family members. TGF and BMP dimers induce heteromeric complex formation between specific 
type II and type I receptors. The type II receptors then transphosphorylate the type I receptors, leading to their activation. Subsequently, 
the type I receptor propagates the signal into the cell by phosphorylating receptor-regulated (R)-Smads, which form heteromeric com-
plexes with Smad4 (common (Co)-Smad) and translocate in the nucleus where by interacting with other transcription factors regulate 
gene transcriptional responses (canonical Smad signaling pathway). Inhibitory (I) Smads 6 and 7 inhibit receptor activation of R-Smads. In 
addition, the activated type I receptors can activate non-Smad pathways (non-Smad signaling pathway).  
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TABLE 1. Misexpression of TGFβ signaling components lead to (cardio)vascular abnormalities. 
Gene  Human disease  Animal model  Reference 
Ligands       
TGF1  Camurati–Engelmann 
disease 
KO: embryonic lethal with vascular defects or postnatal lethality 
from autoimmune disease. 
[13-16] 
TGF2  Kawasaki disease  KO: aortic arch defects, cardiac septal defects, perinatal lethality.  [17,18] 
TGF3  unknown  KO: cleft palate, delayed lung maturation, die shortly after birth.  [19,20] 
Receptors       
TRII  MFS2, LDS  KO: embryonic lethal, vascular defects  [21,136] 
TRI/ALK5  LDS  KO: embryonic lethal, angiogenesis defects  [22,145,146] 
ALK1 
 
HHT 
 
KO: embryonic lethal, reduced VSMC differentiation, dilated ves-
sels, AVMs 
[23,24] 
 
BMPRII  PAH  KO: pre-angiogenesis lethality 
Transgenic BMPR2-mutant allele: pulmonary hypertension 
[25-27] 
Accessory receptors       
ENG (endoglin)  HHT  KO: embryonic lethal due to vascular defects, reduced vSMC dif-
ferentiation, heart defects.  
Het: vascular lesions similar to HHT. 
[28-30] 
Soluble Endoglin 
 
TGFBR3 (betaglycan) 
Pre-eclampsia 
 
Familial intracranial aneurysm 
 
 
KO: poorly formed cardiac septa, incomplete compaction of ven-
tricular walls 
[51] 
 
[31] 
Smads       
Smad1  Unknown  KO: embryonic lethal due to defects in chorion-allantoic circulation  [32] 
Smad3  Aortic aneurysm-osteoarthritis 
 
  [33-37] 
Smad4  JP and HHT 
 
KO: embryonic lethal  [38-40] 
Smad5  Unknown  KO: embryonic lethal due to angiogenesis defects  [41-43] 
Smad6  Unknown  KO: heart abnormalities, aortic ossification and elevated blood 
pressure 
[44] 
Smad7  Unknown  KO: embryonic lethal due to cardiovascular defects  [45] 
Smad8  PAH  Defective pulmonary vascular remodeling  [46] 
Abbreviations: KO, knockout; Het, heterozygous; AVMs, arteriovenous malformations; LDS, Loeys–Dietz syndrome; MFS2, Marfan syn-
drome type 2; HHT, hereditary haemorrhagic telangiectasia; PAH, pulmonary arterial hypertension; JP, Juvenile polyposis; VSMC, vascular 
smooth muscle cell. 
 
 
Numerous  examples  of  divergent  and  contra-
dictory responses of ECs to TGF have been reported. 
It is well accepted today that the TGF paradox is due 
to a number of factors which significantly alter how 
ECs respond to TGF: cellular density, TGFβ concen-
tration,  duration  of  treatment,  presence  of  serum 
components, surrounding matrix, micro/macrovessel 
origin of ECs and also species derivation [3, 4, 47, 48]. 
The inhibitory effects of TGFβ on EC migration and 
proliferation  are  mediated  by  the 
TGF/ALK5/Smad2/3  signaling  pathway.  In  con-
trast, TGFβ signaling via the TGF/ALK1/endoglin 
leads  to  proliferation  and  migration  [9,  49].  It  was 
demonstrated that despite that the two pathways are 
opposed to each other, ALK5 is required for efficient 
ALK1 signaling and the ratio of the two receptors as 
well  as  endoglin  expression  determines  the  relative 
response to TGFβ [9, 49]. Interestingly endoglin can be 
shed  off  the  EC  membrane  and  result  to  a  soluble 
form  (solEng).  solEng  was  shown  to  interfere  with 
angiogenesis and high levels of solEng contribute to 
EC  dysfunction  that  is  observed  in  preeclampsia. 
solEng inhibits VEGF-induced angiogenesis, EC pro-
liferation [50-52] as well as tumor growth. It has been 
suggested that solEng exerts its effects by inhibiting 
TGF signaling [52]. However, recent studies revealed 
that solEng specifically binds to BMP9 and 10, sug-
gesting that solEng may exerts its effects by interfer-
ing  with  BMP9/10  signaling  in vivo  [50].  It  will  be 
interesting  to  characterise  the  exact  mechanism  by 
which  solEng  interferes  with  vascular  endothelial 
growth factor (VEGF)-induced angiogenesis. It can be 
hypothesized that solEng by scavenging TGF ligands 
affects the delicate balance required for angiogenesis. 
In  addition  to  the  control  of  TGFβ  signaling  by  its 
classical  receptors,  additional  receptor  associated Int. J. Biol. Sci. 2012, 8 
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proteins  have  been  identified  for  TGFin  ECs.  For 
example, vascular endothelial (VE)-cadherin has been 
shown to recruit TGF-β receptors I and II into an ac-
tive  receptor  complex  and  regulate  TGFβ  signaling 
[53]. Moreover, the cytoplasmic domain of ALK1 was 
demonstrated to bind casein kinase (CK)2β, the regu-
latory subunit of protein kinase CK2, which results in 
enhancement of ALK1 signaling [54]. 
BMPs have also been implicated in EC function 
and  angiogenesis.  BMP2,  -4,  -6  and  -7  have  been 
shown to induce angiogenesis, EC proliferation and 
migration [3, 4, 8]. Interestingly, although BMP4 was 
shown to induce capillary sprouting in a EC spheroid 
sprouting  assay  [55],  other  reports  have  suggested 
that BMP4 inhibits basal and VEGF  induced angio-
genesis  in  a  human  umbilical  vein  EC 
(HUVEC)-fibroblast  sprouting  angiogenesis  assay 
[56]. Other BMPs, such as BMP9, have also inhibitory 
effects on EC activation, proliferation and angiogene-
sis [10, 57, 58]. However, BMP9 was also reported to 
induce angiogenesis in vivo and EC proliferation [59]. 
Additionally,  BMP9  in  cooperation  with  TGF  can 
induce tumor angiogenesis by inducing EC prolifera-
tion [60]. This BMP9 paradox needs to be further in-
vestigated  and  the  factors  and  signaling  molecules 
which determine the pro- or anti-angiogenic effect of 
BMP9 need to be characterized. The effects of BMPs 
on EC function and angiogenesis can be modulated by 
expression of different BMP antagonists and regula-
tors. BMPER is a differentially expressed protein in 
embryonic endothelial precursor cells. It was shown 
initially that BMPER interacts with BMPs and when 
overexpressed antagonizes their activity [61]. In con-
trast, in a BMPER-deficient zebrafish model BMPER 
behaves  as  a  BMP  agonist.  Moreover,  depletion  of 
BMPER from ECs results  in reduced sprouting and 
BMPER is required for the pro-angiogenic effects of 
BMP4 [61]. These results suggest that BMPER plays a 
pivotal role in fine-tuning BMP activity in angiogene-
sis. Another BMP antagonist induced by hypoxia is 
chordin-like 1 (CHL-1). CHL-1 was shown to antago-
nize the anti-angiogenic effects of BMP4, and alters 
the homeostatic balance between BMP4 and VEGF to 
synergize in driving retinal angiogenesis [56]. Matrix 
GLA  protein  (MGP)  is  expressed  in  EC  and  plays 
crucial role in EC function by affecting BMP, TGF 
and  VEGF  signaling  [62].  MGP  inhibits  BMP2  and 
BMP4 activity by direct interaction as determined by 
co-immunoprecipitation  [62,  63],  while  potentiates 
TGF signaling. It was suggested that MGP induces 
VEGF  expression  and  angiogenesis  by  potentiating 
TGF signaling, thereby  leading to increased VEGF 
expression and angiogenesis. 
TGF signaling does not affect only proliferative 
and migratory EC responses, it also affects vascular 
permeability. Inhibition of TGF signaling by the of 
TRI/ALK5  kinase  chemical  inhibitor  SB431542  re-
sults in increased expression of the EC specific com-
ponent Claudin-5 and inhibits expression of adhesion 
molecules [64]. One of the best characterized factors 
which can modulate the EC barrier is VEGF. TGFβ is a 
known regulator of VEGF in a variety of cell types, 
including epithelial cells [65], macrophages [66], os-
teoblasts [67] and perivascular cells [68]. Thus, TGF 
can  modulate  EC  barrier  properties  by  influencing 
VEGF synthesis in the capillary compartment. TGF 
can have also direct effects on EC permeability. Ex-
ogenous TGF can increases permeability in EC cul-
tures [69, 70]. However, inhibition of TGFβ signaling 
by  neutralizing  TGF  antibody  or  by  SB431542  in 
co-cultures of brain ECs and pericytes [71] or inhibi-
tion of TGF signaling by the SB431542 in retinal ECs 
and  mural  cell  precursors  co-cultures  [72]  leads  to 
increased EC permeability. In addition, it was shown 
that TGF contributes to the maintenance of the EC 
barrier properties  of the retinal  microvasculature  in 
vivo. Systemic inhibition of TGFβ in adult mice led to 
increased  vessel  permeability  as  demonstrated  by 
decreased association between the tight junction pro-
teins  ZO-1  and  occludin  [72]. Moreover,  adenoviral 
infection  with constitutively active ALK5 (caALK5), 
but not caALK1, induces EC retraction by decreasing 
EC permeability [73]. In addition in the EC-specific 
Smad4 knockout mice it has been reported that EC 
permeability defects, due to impaired EC gap junction 
assembly,  lead  to  impaired  vessel  maturation  and 
embryonic lethality [74]. Moreover, thrombospondin, 
an activator of latent TGF, could rescue the increased 
vascular permeability and impaired vascular matura-
tion  reported  in  Akt1  knockout  mice  [75].  Interest-
ingly, inhibition of TGF signaling  in vivo by phar-
macological inhibition of ALK5 resulted in enhanced 
delivery  of  nanoparticles  to  the  tumor  tissue  extra-
vascular space due to increased vessel leakiness [76]. 
In  addition,  solEng  disrupts  EC  function  and  thus 
results in enhanced capillary permeability. Taken to-
gether,  these  studies  suggest  that  TGF  signaling 
plays a critical role in EC function and as a result in 
vascular development and vascular function. 
TGF signaling in mural cells 
TGF signaling besides operating as a rheostat 
that controls EC differentiation, viability and function, 
it  plays  also  important  role  in  smooth  muscle  cell 
(SMC)  differentiation  and  function.  Several  studies 
provided  evidence  that  SMCs  are  a  major  cell  type Int. J. Biol. Sci. 2012, 8 
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through  which  TGFβ  affects  vascular  development 
and disease. TGF upregulates differentiation mark-
ers and induces contractile function in SMC precur-
sors  [77].  TGF  potentiates  vascular  SMC  (VSMC) 
differentiation  by  increasing  the  expression  of 
-smooth  muscle  actin  (SMA)  and  smooth  muscle 
myosin  [78,  79].  At  low  concentrations  it  promotes 
proliferation of SMC, whereas, at high concentrations 
it inhibits SMC proliferation and migration [80-82]. It 
was  shown  that  TGF-induced  expression  of  SMC 
marker genes involves activation of protein kinase N 
(PKN) and p38 MAPK pathways resulting in differ-
entiation  of  SMCs  [83].  TGF1  regulates  phenotype 
transition in SMC by regulation of specific contractile 
proteins  such  as  SMA,  SM22  and  calponin  1  in 
different cells including 10T1/2 cells, neural crest cells 
and fibroblasts [84-86]. In the neural crest stem cell 
line  Monc-1,  RhoA  modulates  TGF1-induced  SMC 
differentiation [87]. In 10T1/2 cells, ERK1/2 activity 
and PI3K/AKT are involved in TGF1-regulated dif-
ferentiation [86, 88]. 
Genetic studies in mice revealed that inactivation 
of critical TGFβ signaling molecules in all cells results 
in failure of vascular development  which correlates 
with a lack of SMC investment of nascent vessels [3, 
4]. In adult arteries, SMCs express TGF receptors and 
appear to respond to TGF by synthesizing ECM that 
contributes to the growth of atherosclerotic and rest-
enotic  lesions  [89-91].  Lineage-specific  ablation  of 
TGF signaling  in  VSMCs resulted in alterations  in 
vascular morphogenesis in mice, including impaired 
elastogenesis and vessel widening [92]. TGFβ actions 
on  SMC  are  both  direct  and  indirect,  mediated 
through  downstream  effects  of  TGF  signaling  in 
other cell types. For example, TGFβ acts directly on 
ECs, with consequent paracrine effects on SMCs [93, 
94]. TGFβ could act directly on cells of the immune 
system, with effects on SMC mediated through alter-
ations in plasma cytokines.  
BMPs play also important role in SMC function. 
BMPs were reported to regulate migration, prolifera-
tion, and apoptosis of VSMCs and to modulate the 
expression  of  SMC  phenotypic  markers  in vitro.  In-
terestingly, the effects of BMPs on VSMCs vary, de-
pending on the anatomic origin of the cells, their state 
of  differentiation  or  dedifferentiation,  and  culture 
conditions. BMP2, BMP4 and to a lesser extent BMP7 
are reported to inhibit VSMC proliferation [95-99]. It 
was shown that BMP2 and BMP7-induced apoptosis 
of  pulmonary  SMCs  (PASMCs)  [100].  It  was  also 
shown that BMP2 inhibits SMC proliferation without 
stimulating  ECM  synthesis  and  that  adenovi-
rus-mediated  transfer  of  the  BMP2  gene  inhibited 
injury-induced  intimal  hyperplasia  suggesting  the 
possibility of therapeutic application of BMP2 for the 
prevention  of  vascular  proliferative  disorders  [97]. 
BMP7  inhibits  TGF  and  platelet-derived  growth 
factor  (PDGF)-BB–induced  SMC  growth  and  stimu-
lates the expression  of SMC-specific markers by in-
ducing p21 and I-Smad expression [101, 102]. In addi-
tion,  BMP7  exhibited  anti-inflammatory  activity  by 
downregulating  intercellular  adhesion  molecule-1 
(ICAM-1) expression [101]. These results suggest that 
BMP7 may be used in clinic in order to prevent vas-
cular proliferative disorders and to maintain vascular 
integrity. In another study, BMP2 was shown to be 
expressed by human aortic SMCs (HASMC) and to 
induce migration of HASMC in a concentration- and 
time-dependent manner. In addition, BMP2 synergis-
tically  induced  PDGF-induced  chemotaxis.  In  con-
trast, BMP2 had no significant effect on HASMC pro-
liferation [98]. Both BMP7 and BMP4 promote apop-
totic cell death in human primary PASMCs by acti-
vating caspase-8 and caspase-9. PASMCs expressing 
mutant  forms  of  BMPRII,  identified  in  idiopathic 
pulmonary  arterial  hypertension  (IPAH)  patients 
were resistant to BMP-mediated proapoptotic effects 
[103]. Interestingly it was shown that pulmonary mi-
crovascular ECs (PMVEC) secrete BMP4 in response 
to hypoxia and promote proliferation and migration 
of VSMCs in a BMP4-dependent fashion [95]. It was 
shown that BMP4 inhibited proliferation of PASMCs 
isolated from proximal pulmonary arteries, but stim-
ulated proliferation of PASMCs from peripheral ar-
teries, and conferred protection from apoptosis. Alt-
hough these differences were not caused by differen-
tial  activation  of  BMP  signaling  pathways,  the 
pro-proliferative  effect  of  BMP4  on  peripheral 
PASMCs was found to be p38MAPK/ERK-dependent 
[99]. The role of BMP signaling in PAH will be dis-
cussed in more detail in following sessions. 
Vascular tone and TGF signaling 
EC-Mural  cell  interactions  are  important  not 
only for the growth and maintenance of intact vessels 
but also for physiological vessel function. Vessel tone 
regulation  is  controlled  by  the  contractile  state  of 
SMC. EC regulate the SMCs contractile function by 
releasing a number of vasoactive soluble factors [104]. 
These  factors  stimulate  either  contraction  or  relaxa-
tion of mural cells and thus modulate capillary flow. 
Nitric oxide (NO) and prostacyclin (PGI2) exert vaso-
dilatory effects on SMCs [105]. NO has also antipro-
liferative effects on SMC. EC dysfunction, including 
decreased  endothelial  nitric-oxide  synthase  (eNOS) 
activity and loss of bioactive NO, plays a prominent 
role in the development of pulmonary arterial hyper-Int. J. Biol. Sci. 2012, 8 
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tension  (PAH)  [106].  On  the  other  hand  endothelin 
(ET)-1  is  a  potent  vasoconstrictor  which  stimulates 
contraction of mural cells via ET-A and ET-B receptors 
and release of NO from ECs via endothelial ET-B re-
ceptors [107]. 
Several studies have suggested that TGF plays 
an important role in the regulation of vascular tone 
and  reactivity,  since  TGF  signaling  is  involved  in 
regulating  the  expression  of  both  vasodilators  and 
vasoconstrictors.  It  was  demonstrated  that 
TGF/ALK5/Smad3 pathway induces EC expression 
of ET-1, resulting in decreased EC migration and pro-
liferation [108, 109]. In addition TGFβ1 induces PGI2 
production by ECs [110], and increases EC levels of 
cycloxygenase-1  [111]  and  prostacyclin-stimulating 
factor [112], which induce synthesis of the vasodila-
tory  molecule  prostacyclin.  In  addition,  iloprost,  a 
prostacyclin analog induces increased TGFβ1 expres-
sion by SMCs [113], suggesting a potential feedback 
mechanism.  TGFβ  regulates  also  eNOS  activity,  the 
enzyme responsible for baseline NO signaling in ECs 
[114,  115].  In  contrast,  addition  of  a  synthetic  NO 
donor  diethylenetriamine  nitric  oxide  adduct 
(DETA)/NO to cultured human coronary SMCs was 
shown to induce TGF mRNA and protein expression 
in  human  coronary  smooth  muscle  cells  [116].  An-
other  study  has  demonstrated  that  aortas  from  NO 
synthase  deficient  mice  displayed  enhanced  basal 
TGF1 activity; ECs from these animals showed in-
creased  Smad  phosphorylation  and  transcriptional 
activity. In the same study it was shown that NO re-
duced the half-life of ectopically expressed Smad2 by 
enhancing  its  ubiquitination.  Thus,  NO  pathway  in 
ECs  interferes  with  TGFβ/Smad2  signaling  by  di-
recting  the  proteasomal  degradation  of  activated 
Smads and may act as a feedback mechanism to limit 
activation of NO by TGFβ [117]. These results suggest 
that, since TGF signaling influences both vasodila-
tors  and  vasoconstrictors,  misregulation  of  TGF 
signaling  may  result  in  perturbation  of  the  vessel 
tone. Consistent with this notion it was shown that 
intravascular infusion of TGF in mice results in de-
creased vascular resistance and vasolidation. In addi-
tion, it was suggested that chronically increased levels 
of TGFβ1 in the brain of Alzheimer leads to impaired 
constriction of cerebral vessels due to impaired ET-1 
mediated contractions [118]. The role of TGF signal-
ing in hypertension will be further discussed in later 
sections. 
Overexpression  of  solEng  in  mice  resulted  in 
impaired peripheral microvessel blood flow response 
and collapsed retinal microvessels [72, 119]. Moreo-
ver, overexpression of solEng leads to brain AVMs in 
mice [120]. In addition, solEng was found to inhibit 
TGFβ-mediated activation of eNOS, thereby affecting 
vascular tone [52]. Similarly, mice heterozygous for 
endoglin  have  a  severely  vasoactive  response  as  a 
result  of  decreased  eNOS  expression  due  to  eNOS 
decreased  half-life  [115].  In  addition  Eng+/−  mice 
exhibit  reduced  matrigel-dependent  capillary  tube 
formation and delayed reperfusion in a hindlimb is-
chemia model [121]. Moreover, it was shown that Ac-
etylcholine-induced  vasorelaxation  it  was  signifi-
cantly increased in adult Eng+/- vs. control vessels. 
These  vasodilatory  responses  were  inhibited  by  the 
nitric oxide synthase inhibitor N (G)-nitro-L- arginine 
methyl  ester  (L-NAME),  suggesting  eNOS  depend-
ence. In addition eNOS uncoupling was observed in 
lung tissues of adult, but not newborn, heterozygous 
mice and was associated with increased production of 
reactive O2 species (ROS) in adult Eng+/- vs. control 
lungs. These data suggest that eNOS-dependent H2O2 
generation in Eng+/- lungs accounts for the height-
ened  pulmonary  vasorelaxation  [122].  In  a  recent 
study  thalidomide  induced  vessel  maturation  by 
mural cell recruitment in Eng-heterozygous mice and 
Hereditary  hemorrhagic  telangiectasia  (HHT)  pa-
tients, partly by inducing PDGF-B expression in ECs, 
further supporting the important role of endoglin in 
EC–SMC interactions [123]. 
BMPs were also shown to play important role in 
vessel  tone  regulation  and  vascular  function.  Addi-
tion of exogenous BMP2 induces expression and ac-
tivity of eNOS in intrapulmonary artery and pulmo-
nary EC preparations [124]. In the same study it was 
shown that BMP2 heterozygous mice develop severe 
hypoxic pulmonary hypertension while BMP4 heter-
ozygous  mice  are  protected.  This  was  shown  to  be 
due  to  decreased  endothelial  nitric  oxide  synthase 
(eNOS)  expression  and  activity  in  the  pulmonary 
vasculature  of  hypoxic  Bmp2+/-  but  not  Bmp4+/- 
mice.  It  was  also  shown  that  activation  of  BMPRII 
promotes pulmonary artery EC (PAEC) survival, pro-
liferation,  and  migration  by  activating  eNOS  [125]. 
BMP2  and  BMP4  were  shown  to  stimulate  eNOS 
phosphorylation resulting in increased eNOS activity. 
Inhibition of eNOS activation by NOS inhibitors hin-
dered  BMP2  and  BMP4  induced  PAEC  migration. 
Interestingly  functional  deletion  of  the  extracellular 
BMP  modulator  BMPER  results  in  reduced  eNOS 
expression  [126].  BMP4  infusion  stimulated  aortic 
NADPH  oxidase  activity  which  led  to  endothelial 
dysfunction and subsequent impaired vasorelaxation 
and increased systolic blood pressure in mice  [127]. 
BMP4 upregulation  has been linked with  hyperten-
sion. Addition of BMP4 in cultured human coronary 
arterial  ECs  exerts  prooxidant,  prohypertensive  ef-
fects [128]. BMP4 treatment of mouse aortaes led to Int. J. Biol. Sci. 2012, 8 
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impaired  endothelium-dependent  relaxations,  exag-
gerated endothelium-dependent contractions via cy-
clooxygenase-2  (COX-2)  upregulation  in  a  reactive 
oxygen species (ROS) dependent manner [129]. It has 
been also reported that increased pulmonary vascular 
remodelling in Alk1+/− mice leads to signs of PAH 
and  it  has  been  shown  that  this  is  associated  with 
eNOS-dependent  ROS  production  and  it  can  be 
averted by anti-oxidant treatment [130]. Interestingly 
prostacyclin analogues were shown to enhance BMP 
induced  Smad1/5  phosphorylation  by  suppressing 
Smad6  expression  [131].  Furthermore,  prostacyclin 
analogues rescued the defects in Smad1/5 phosphor-
ylation in PASMCS from PAH patients and inhibited 
SMC proliferation and prevented PAH progression in 
the monocrotaline rat model of PAH [131]. 
Perturbation of TGF signaling in cardiovas-
cular diseases 
The  critical  role  of  TGF  signaling  in  vascular 
function  was  further  verified  by  studies  in  human. 
Genetic analysis revealed that mutations in genes of 
the TGF family or genes which affect TGF signaling 
function  lead  to  vascular  dysfunction  and  disease 
(Table 1).  
Mutations in the ALK1 and endoglin genes lead 
to an autosomal dominant vascular dysplasia known 
as HHT. HHT is characterized by the development of 
telangiectasias and AVMs [3, 4]. HHT type 1 is caused 
by mutations in endoglin [28, 132], whereas type 2 is 
due to mutations in ALK1 [23, 24]. Recently, it was 
reported that a subset of patients with juvenile poly-
posis (JP), carrying mutations in the Smad4 gene, can 
also  develop  HHT  [38].  Interestingly  targeted  dele-
tions of Acvrl1 (ALK1), TR1 (ALK5), TR2 and Eng 
in mice result in vascular abnormalities highly remi-
niscent of those described in patients with HHT. The 
vascular  abnormalities  and  fragile  leaky  vessels  are 
due to abnormal EC proliferation and SMC recruit-
ment [3]. Thalidomide treatment of HHT patients was 
shown to enhance blood vessel stabilization and re-
duce nosebleed frequency [123]. Moreover, it has been 
shown that VEGF levels are elevated in skin telangi-
ectatic  lesions  of  HHT  patients  and  that  an-
ti-angiogenic drugs, such as thalidomide and bevaci-
zumab (anti-VEGF antibody), are effective in treating 
gastrointestinal  bleedings  and  liver  AVMs,  respec-
tively [133-135]. 
Endoglin can  be shed from the cell surface by 
MMP14 and this result in a soluble form of endoglin 
[51]. Excessive production of solEng by trophoblasts 
in placenta has been reported in patients affected by 
pre-eclampsia [52], whether this is caused by exces-
sive  MMP14  activity  remains  to  be  shown. 
Pre-eclampsia  is  characterized  by  EC  dysfunction 
resulting  in  vasoconstriction,  endo-organ  ischemia 
and increased vascular permeability which leads to a 
raise in blood pressure, is a major cause of maternal, 
fetal, and neonatal mortality [52]. It was shown that 
solEng  interferes  with  EC  function  [51,  52].  Recent 
studies have shown that solEng can bind to BMP9 and 
BMP10  and  inhibit  their  signaling  [50].  In  addition 
solEng can inhibit VEGF induced angiogenesis in vitro 
and  in  vivo.  Although  the  exact  mechanism  is  not 
known these results suggest that sol-endoglin may be 
used in anti-angiogenic therapeutic interventions. 
Marfan  syndrome  (MFS)  is  a  genetic  disorder 
characterized by defects in the cardiovascular system 
and in aorta and heart valves due to increased TGF 
signaling activity. MFS is caused by mutations in the 
fibrillin gene [136, 137] and affects the skeletal system, 
ocular  system,  cardiovascular  system,  pulmonary 
system as well as other organs. Fibrillin interacts with 
LTBP  and  control  TGF  bioavailability  [138].  MFS 
type 2 is caused by mutation in the TβRII gene locus. 
Interestingly it was shown recently that mutations in 
TβRII associated with MFS2 and LDS have differential 
effects on TGF-induced Smad and ERK signaling. It 
was  suggested  that  the  balance  between 
TGF-induced Smad and ERK might be an important 
determinant  of  phenotypic  severity  in  disorders  re-
lated to different mutations in TβRII [139]. In a mouse 
model of MFS inhibition of TGF signaling by a TGF 
neutralizing antibody or the angiotensin II type 1 re-
ceptor inhibitor losartan resulted in decreased aortic 
root dilatation, elastic fiber degeneration, Smad2 ac-
tivation, and reversal of skeletal myopathy [140-142]. 
These  results  further  confirmed  the  contribution  of 
excess  TGF  signaling  to  the  vascular  pathology  of 
MFS.  Although  the  mechanism  by  which  losartan 
protects against aortic aneurysm and reduces Smad2 
activation is not fully understood clinical studies have 
been initiated and losartan is now used in clinical tri-
als with MFS [143]. Recent observations demonstrated 
an essential role for the TGF non-Smad signaling in 
aneurysm pathogenesis in MFS mice. It was demon-
strated  that  TGF-induced  ERK1/2  activation  con-
tributes to aortic aneurysm progression and that an-
tagonism  of  this  pathway  may  be  therapeutically 
useful [144]. 
The  Loeys-Dietz  (LDS)  syndrome  is  an  aor-
tic-aneurysm  syndrome  characterized  by  cardiovas-
cular manifestations caused by inactivating mutations 
in the TGF type I or II receptors [145, 146]. Although 
the molecular mechanism of LDS is still poorly un-
derstood, LDS is most likely related to TGF signaling 
defects. Interestingly the aortae of patients with LDS, Int. J. Biol. Sci. 2012, 8 
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who  carry  heterozygous  inactivating  mutations  in 
either TβRII or TβRI display increased TGF–SMAD 
signaling and fibrosis [146]. 
Recently, mutations in Smad3 have been linked 
with a syndrome characterised by aneurysms, dissec-
tions  and  tortuosity  throughout  the  arterial  tree  in 
association with mild craniofacial features and skele-
tal and cutaneous anomalies [35]. In addition the af-
fected individuals displayed early-onset osteoarthri-
tis.  These  findings  implicate  the  TGFβ  signaling 
pathway as a putative pharmacological target for the 
development of new treatment strategies for arterial 
wall anomalies and osteoarthritis. 
As discussed earlier TGF signaling is critical for 
vascular tone regulation and its perturbation leads to 
impaired blood flow. Hypertension is a cardiovascu-
lar risk factor which contributes to the development of 
organ  damage  such  as  renal  sclerosis,  stroke,  and 
coronary heart disease. Recent studies have suggested 
that there is a link between increased levels of circu-
lating TGF and hypertension [147, 148]. It has been 
shown  that  emilin,  an  extracellular  matrix  protein, 
regulates TGFβ availability and that it is involved in 
the  regulation  of  arterial  diameter.  Genetic  studies 
have  shown  that  disruption  of  emilin-1  expression 
results  in  increased  conversion  of  pro-TGF  to  the 
mature form and as a result increased TGF signaling 
[149]. This leads to a reduction in arterial lumen di-
ameter with a resultant increase in vascular resistance 
and hypertension. It has been postulated that this is 
due to increased TGF signaling which leads to cyto-
stasis of VSMCs and decreased arterial wall expan-
sion.  On  the  other  hand,  reduced  arterial  diameter 
and hypertension may be a secondary consequence of 
vascular remodelling in mice. This phenotype could 
be rescued genetically by disruption of one the TGF 
alleles  and  reduction  of  TGF  levels  [149].  Interest-
ingly, missregulation and reduction of TGF signaling 
in ECs, due to increased levels of solEng, results also 
in increased blood pressure in pre-eclampsia [52]. 
IPAH is a disease characterized by constriction 
of the pre-capillary pulmonary arteries, which results 
in sustained pulmonary arterial pressure. IPAH pa-
tients  are  prone  to  heart  failure  [150,  151].  PAH  is 
characterized  by  excessive  proliferation  of  ECs  and 
VSMCs [152, 153], increased  vascular inflammation, 
increased vasoconstriction and reduced dilation. Ge-
netic studies in human revealed that loss of function 
mutations  in  BMP  type  II  receptor  (BMPRII)  were 
linked with heritable pulmonary arterial hypertension 
(HPAH) [26, 154-157]. BMPRII expression by ECs and 
VSMCs  is  significantly  reduced  not  only  in  HPAH 
cases  with  a  BMPRII  mutation,  but  also  in  patients 
with  secondary  PAH  [158-160].  Mice  expressing  a 
BMPR-II  mutant  lacking  C-terminal  tail  in  the  pul-
monary  SMCs  develop  pulmonary  vascular  lesions 
similar to PAH. Interestingly it was shown that dis-
ruption of BMPRII in PASMCs leads to reduced BMP2 
and  BMP4  signaling,  while  signaling  by  BMP6  and 
BMP7 is enhanced [161]. Furthermore, it was shown 
that  BMP4  is  upregulated  in  hypoxia-induced  PAH 
and that heterozygous Bmp4/lacZ mice are protected 
from  the  development  of  hypoxia-induced  PAH, 
VSMC  proliferation,  and  vascular  remodelling.  Hy-
poxia induced PMVEC to secrete BMP4 and promoted 
proliferation  and  migration  of  VSMCs  in  a 
BMP4-dependent  manner  [95].  In  addition  reduced 
BMP/Smad signaling resulted in activation of the p38 
MAPK pathway which led in aberrant PASMC pro-
liferation [99, 162, 163].  
Recently mutations in the downstream mediator 
Smad8, which is highly expressed in the pulmonary 
vasculature, were identified in patients with HPAH 
[164]. This is surprising, since loss of Smad8 function 
in canonical BMP signaling is largely compensated by 
Smad1/5. In the same study it was shown that Smad8 
mutations  lead to decreased miR-21 levels and that 
miR-21  overexpression  results  in  anti-proliferative 
effects  in  PAEC  and  PASMC.  Overexpression  of 
Smad8 corrected microRNA processing and reversed 
the  hyperproliferative  phenotype  [165].  Loss  of 
Smad8 function in mice results in abnormal vascular 
remodeling,  increased  vascular  inflammation  and 
pulmonary tumors [46]. Interestingly, certain HHT2 
patients  develop  PAH-like  syndromes,  suggesting 
that  ALK1  mutations  can  also  be  involved  in  PAH 
[166, 167]. 
The role of TGFβ in PAH has been also investi-
gated. Abnormal TGF-β signaling has been observed 
in  the  pulmonary  vasculature  of  PAH  patients  [96, 
168].  TGF induces apoptosis in PMVEC. Although 
TGF induced both Smad2 and Smad1/5 activation, 
only  Smad2  was  shown  to  be  important  in 
TGF-induced apoptosis of PMVEC. Thus, imbalance 
of ALK1 and ALK5 may contribute to the develop-
ment of pulmonary artery hypertension [169]. Other 
studies  provided  evidence  that  increased TGFβ  sig-
naling  participates  in  the  pathogenesis  of  experi-
mental  PAH.  The  development  of  Monocrotal-
ine-induced-PAH was associated with increased vas-
cular cell apoptosis and increased TGFβ signaling as 
documented  by  phosphorylated  Smad2  expression. 
Inhibition of TGFβ signaling significantly attenuated 
the development of the PAH and reduced pulmonary 
vascular remodeling [170]. 
Although it is recognized that PAH is character-
ized by increased number of SMCs, this may not be Int. J. Biol. Sci. 2012, 8 
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only due to increased proliferation of SMCs. Evolving 
experimental  evidence  suggests  alternative  sources 
for  SMC  cells.  It  has  been  suggested  that  ECs  may 
transdifferentiate  into  mesenchymal–like  cells  ex-
pressing SMA, resulting thus in increased numbers of 
SMC-like cells in vascular pathologies. This hypothe-
sis is supported by the demonstration that transdif-
ferentiation  of  pulmonary  arteriolar  ECs  into 
SMC-like  cells  occurs  during  hypoxia-induced  pul-
monary  vascular  remodeling  and  is  regulated  by 
myocardin [171]. This process during which ECs lose 
endothelial  features,  and  acquire  mesenchymal-like 
characteristics  has  been  termed  Endotheli-
al-to-Mesenchymal  Transition  (EndoMT).  Several 
groups have provided evidence that EndoMT is criti-
cal in early vascular development. For example, it was 
shown that EndoMT plays an important role in aortic 
and pulmonary artery development [172, 173]. Future 
studies will shed more light into the role of EndoMT 
in the pathology of PAH and other vascular diseases. 
TGF signaling in atherosclerosis and vascular 
calcification 
Atherosclerosis  is  a  chronic  inflammatory  dis-
ease of the arterial wall leading to regional ischemia 
and  ischemic  complications  such  as  myocardial  in-
farction and stroke, which greatly contribute to mor-
bidity and mortality. Atherosclerosis is characterised 
by  immunological  mechanisms  leading  to  vascular 
inflammation  and  plaque  formation  [174]  (Fig.  2). 
TGF ligands, its receptors as well as Smad proteins 
have been found to be expressed in fibro-fatty lesions 
and fibrous plaques [175-177]. Consistent with such 
an expression profile, TGF has been found to affect 
the properties and function of all the cell types that 
are known to be present in atherosclerotic lesions such 
as ECs, SMCs, monocytes/macrophages, platelets, T 
cells and myofibroblasts. It has been suggested origi-
nally that TGF exerts anti-atherogenic effects  [178] 
thus  having  a  protective  role  either  by  regulating 
vascular  cell  proliferation,  plaque  stability,  immune 
system function or by its anti-inflammatory function 
[179, 180]. Interestingly, it was shown that there is an 
inverse relationship between serum TGF1 levels and 
the development of atherosclerosis and that concen-
tration of active TGF1 is severely depressed in ad-
vanced  atherosclerosis  [181-183].  In  addition,  muta-
tions of TRII have been associated with atheroscle-
rotic and restenotic vascular cells [184]. In contrast to 
the  atheroprotective  effects  of  TGF  several  studies 
have  shown  that  atherogenic  stimuli  such  as  shear 
stress [185], oxidized cholesterol [186], angiotensin II 
[187]  or  growth  factors  such  as  PDGF  result  in  in-
creased TGF expression [188]. At the same time in-
creased  TGF1  expression  was  found  in  atheroscle-
rotic clinical specimens and increased levels of TGF1 
were  correlated  with  advanced  atherosclerosis  [189, 
190] (Fig. 2).  
Endoglin expression was shown to be upregu-
lated in VSMC in human atherosclerotic plaques fur-
ther supporting a role for endoglin in the maintenance 
of vascular integrity and in the response of the vessel 
wall to injury [89, 191]. In addition it was shown that 
solEng levels are significantly higher in diabetic pa-
tients and in patients with hypertension and diabetes 
[192].  Higher  solEng  levels  were  found  in  patients 
with diabetes who had retinopathy, in patients with 
diabetes who had a high probability of 10-year car-
diovascular  risk,  and  in  patients  with  diabetes  and 
hypertension who had three or more damaged target 
organs than in those  with no organs affected  [192]. 
Changes in solEng plasma levels have been reported 
in other pathologies such as atherosclerosis and cor-
onary  artery  disease  [193].  Also,  changes  of  solEng 
plasma  levels  after  an  acute  myocardial  infarct  are 
accurate predictors of acute mortality in these patients 
[194]. 
Several studies suggested that BMPs play also an 
important role in atherosclerosis  by modulating EC 
inflammation and cell differentiation. It  was shown 
that BMP4 is increased in response to the high fat diet 
and  BMP2  and  -4  have  been  implicated  in  proin-
flammatory  effects  in  the  endothelium  [195-197]. 
Furthermore,  interference  with  the  BMP  pathway 
leads to reduced, while enhanced BMP activity results 
in  increased  atherosclerotic  lesion  formation  in 
Apolipoprotein  (Apo)E  knockout  mice  [195-197].  It 
was suggested that this might be due to the effects of 
BMP signaling on EC function. BMP2 and BMP4 have 
been implicated as mediators of endothelial inflam-
mation  in  response  to  shear  stress,  oxidative  stress 
and pro-inflammatory cytokines [198, 199]. Whether 
these effects are due to effects on  mononuclear cell 
function is not known (Fig. 2).  
A  histological  and  clinical  hallmark  of  athero-
sclerosis is arterial calcification. Although initially it 
was considered that vascular calcification is a passive 
process of accumulation of dying cells, later studies 
suggested that vascular calcification is a highly regu-
lated process. Several studies have provided evidence 
that vascular calcification is the result of an osteogenic 
process, which leads to mineralisation of the ECM and 
cell differentiation towards osteoblast-like lineages. It 
has  recently  become  appreciated  that  under  certain 
pathologic  contexts  and  culture  conditions,  VSMCs 
can differentiate to acquire an osteogenic phenotype, 
and  express  lineage  markers  consistent  with 
bone-forming cells as well as calcification-regulating Int. J. Biol. Sci. 2012, 8 
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proteins commonly found in bone [200-202]. Consid-
erable evidence suggests that TGFβ family members, 
particularly the BMPs, are important modulators  of 
vascular calcification [203, 204], probably by inducing 
ECM production that is amenable to mineralization 
and by favoring differentiation toward osteoblast-like 
lineages (Fig. 2). After the demonstration that BMP2 is 
expressed in calcified human atherosclerotic plaques 
it  was  shown  that  BMPs  can  direct  osteogenic  pro-
gramming  of  vascular  mesenchymal  progenitors  of 
the  pericyte  lineage  [205].  Later  it  was  shown  that 
BMP signaling as well as a variety of inflammatory 
stimuli can promote expression of osteoblast lineage 
markers  such  as  alkaline  phosphatase  in  cultured 
VSMCs [200, 201, 206-209]. Treatment  of SMC  with 
BMP2  enhanced  vascular  calcification  via  increased 
phosphate uptake and  induction of osteogenic phe-
notype  modulation  in  SMC  [210].  Moreover,  BMPs 
may induce VSMC to express proteins, such as oste-
oprotegerin  which  may  confer  protection  from  vas-
cular calcific and atheromatous disease [211]. Recent-
ly, it was shown that inhibition of BMP signaling in 
ApoE−/− mice by transgene expression of MGP re-
sulted in diminished Smad1/5/8 signaling, as well as 
reduced inflammation, lesion formation, and calcifi-
cation after fat feeding [197]. On the other hand MGP 
deficient  ApoE−/−  mice  displayed  enhanced 
Smad1/5/8 signaling and extensive medial calcifica-
tion as previously reported [197]. In addition, BMPs 
were shown to be increased in diabetic vasculopathy. 
BMP2 was shown to be expressed in adventitial myo-
fibroblasts in the aorta of fat-fed diabetic Low-density 
lipoprotein receptor (LDLR)−/− mice and to induce 
an osteogenic phenotype in a subset of the myofibro-
blasts by inducing Msx2 expression, which is associ-
ated with bone formation [212]. In diabetic rats both 
BMP2 and BMP4 were shown to  be induced. Inter-
estingly,  transgenic  expression  of  MGP  resulted  in 
reduced BMP activity and diminished calcification in 
the entire media [213]. MGP, noggin and chordin are 
downregulated  in  dedifferentiated  VSMCs,  which 
would  make  them  more  susceptible  to  BMP  action 
[195].  Thus,  the  balance  between  endothelial  BMPs 
and their inhibitors may determine the health of the 
endothelium, and an efficient limitation of endothelial 
BMP  activity  may  confer  protection  against  athero-
sclerosis. TGF was also shown to play important role 
in vascular calcification. TGF is present in calcified 
aortic valves and regulates vascular calcification and 
osteoblastic differentiation of VSMCs [214, 215]. 
 
 
 
 
 
Figure 2. Involvement of TGF and BMP signaling in atherosclerosis. Elevated expression of TGF and BMP2 and -4 during athero-
sclerosis leads to lesion formation and vascular calcification. Vascular calcification may be a result of smooth muscle cells (SMC) dedif-
ferentiation to osteogenic SMC or differentiation of ECs in to mesenchymal osteogenic cells via endothelial to mesenchymal transition 
(EndoMT). 
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It  has  been  proposed  that  during  lesion  for-
mation  enhanced  BMP  signaling  may  promote  de-
velopmental conditions and trigger the differentiation 
of multipotential susceptible cells into the osteogenic 
lineage. It has been suggested that several cell popu-
lations might enter into an osteocondrogenic lineage 
reprogramming, however, the relative contribution of 
the  respective  cell  population  to  local  osteogenesis 
and vascular calcification in different arteriosclerotic 
disease states remains to be established. These include 
the calcifying vascular cells isolated from the aortic 
media  [205,  216].  Myofibroblasts  present  in  the  ad-
ventitia  of  diabetic  and  hyperlipidemic  LDLR−/− 
mice [212] may also acquire an osteogenic phenotype. 
Pericytes have recently emerged as multipotent adult 
mesenchymal stem cells and it was shown that they 
have osteogenic potential [217]. BMPs can direct os-
teogenic  programming  of  vascular  mesenchymal 
progenitors of the pericyte lineage; however, the rela-
tive contribution of pericytes to osteogenic vascular 
calcification has yet to be clarified. It was proposed 
that VSMC can differentiate and acquire an osteogenic 
phenotype and this may directly contribute to medial 
calcific  vascular  disease.  VSMC  transdifferentiation 
was also shown to contribute to the  vascular endo-
chondral ossification mechanisms in mice [218]. Cir-
culating stem cells may also contribute to osteogenic 
changes in the artery wall. It has been suggested re-
cently  that  vascular  ECs  might  enter  into  an  oste-
ocondrogenic  lineage  reprogramming  [219].  Several 
studies have suggested that EC plasticity allows EC to 
transdifferentiate  into  messenchymal  cells  during 
embryonic  development  [220]  or  as  a  response  to 
chronic inflammation [221, 222]. Endothelial differen-
tiation  towards  a  mesenchymal  phenotype  has  re-
cently been linked to ALK2 activity. It was demon-
strated that expression of a constitutively active form 
of the ALK2 type I receptor in mice causes EndoMT; 
EC  cells  acquire  a  stem  cell–like  phenotype  which 
enables  them  to  undergo  osteogenic  differentiation 
[219]. Patients with fibrodysplasia ossificans progres-
siva  are  characterized  by  heterotopic  calcification, 
caused by mutations in the ALK2 gene. It was shown 
that  chondrocytes  and  osteoblasts  of  these  patients 
expressed  EC  markers.  In  addition,  treatment  of 
HUVECs  and  human  cutaneous  microvascular  ECs 
(HCMECs)  with  either  TGF2  or  BMP-resulted  in 
induction  of  EndoMT,  whereas  BMP7  and  VEGF 
blocked it [219]. TGF has also been reported to in-
duce EndoMT in ECs  in vitro [223-226]. In addition 
TGF1  induces  EndMT  in  EC  progenitors  via  the 
TGF/ALK5/Smad2  signaling.  TGF  treatment  re-
sulted in decreased expression of endothelial markers 
and while inducing mesenchymal marker expression 
as  well  as  cytoskeletal  rearrangements,  which  pro-
moted cells to acquire a contractile phenotype [225]. 
Concluding remarks 
It is well appreciated that members of the TGF 
family  play  a  crucial  role  in  the  regulation  of  both 
normal  and  abnormal  vascular  function.  TGF  lig-
ands regulate angiogenesis through their actions ei-
ther on ECs and/or on mural cells, affecting e.g., pro-
liferation,  migration  and  most  importantly  cell  dif-
ferentiation, underlying the important role of TGF 
signals in angiogenesis. TGF signaling regulates also 
EC/SMC interactions and by this way further control 
vascular function. Missregulation of TGF signaling, 
both in human and mice, leads to vascular dysfunc-
tion and vascular pathologies. Recently, it has become 
evident that TGF signaling acts as a rheostat rather 
than an on-off switch to regulate vascular function. 
The  effects  of  TGF  ligands  are  highly  context  de-
pendent. Ligand concentration, cell density, cell type, 
media and culture conditions may determine specific 
cellular responses to TGF family members. In addi-
tion the effects of TGF signals depend on the inter-
play between different members of the TGF family.  
Due to its role in cardiovascular disease patho-
physiology,  TGF  signaling  components  have  been 
considered  as  potent  therapeutic  targets  in  a  wide 
spectrum of cardiovascular disorders. Several classes 
of  inhibitors  targeting  ligand-receptor  interactions 
have  been  developed  to  interfere  with  the  TGF 
pathway. Such inhibitors include TGF neutralizing 
antibodies,  anti-receptor  antibodies,  receptor  ecto-
domain proteins that act as ligand traps. In addition 
small chemical inhibitors have been developed which 
interfere with the kinase activity of type I TGF re-
ceptor. In a mouse model of MFS it was shown that 
systemic delivery of pan-TGF neutralizing antibod-
ies  prevents  aortic  aneurysm,  developmental  em-
physema and skeletal myopathy [138, 141, 227]. Ad-
ministration of losartan had similar effects by inhib-
iting TGF ligand expression, receptors, and activa-
tors  such  as  thrombospondin  and  MMPs  [227]. 
However, the same anti-TGFβ neutralizing antibody 
treatment  induced  lethal  cardiovascular  pathologies 
in  mouse  models  of  aneurysm  and  atherosclerosis 
[228, 229]. In addition, preclinical observations sug-
gested  that  angiotensin  II  type  I–receptor  blockade 
results in decreased TGFβ signaling. This was trans-
lated into clinical studies and the effects of angioten-
sin II type I inhibitors are being studied in MFS pa-
tients [140, 143]. Based on the observations that the 
pathology of PAH results from a misbalance in BMP 
and  TGF  signaling  pathways,  targeting  of  these Int. J. Biol. Sci. 2012, 8 
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pathways  has been considered as a potential  thera-
peutic intervention for the treatment of PAH. Inhibi-
tion  of  TGF  signaling  as  a  potential  treatment  of 
PAH is under investigation [230, 231]. Specific BMP 
agonists may also be useful in treatment PAH. Inter-
estingly, administration of iloprost also restores defi-
ciency  in  Smad1/Smad5  phosphorylation  and  Id1 
levels in BMPRII deficient PASMCs, while prostacy-
clin  analogues  are  currently  used  for  treatment  of 
PAH  in  clinic  since  they  restore  Id1  expression  in 
PASMCs [131]. Both TGF and BMP signaling have 
been implicated in atherosclerosis and vascular calci-
fication.  Several  therapeutic  approaches  to  interfere 
with BMP signaling such as recombinant ligands, an-
tagonists, soluble receptors and neutralizing antibod-
ies  have  been  exploited  [232,  233].  Recently  Dorso-
morphin, a BMP receptor antagonist [233], has been 
succesfully used for inhibition of BMP signaling.  In 
addition,  identification  of  novel  molecules,  such  as 
LDN-193189 with enhanced specificity to antagonize 
BMP  receptor  activity  [234]  offer  new  therapeutic 
possibilities. 
In  conclusion,  due  to  its  multifunctional  and 
context  dependent  function  interference  with 
TGF-dependent  processes  must  be  carefully  de-
signed and the effects of TGF signaling or its inhibi-
tion  on  the  different  cell  types  involved  must  be 
carefully studied. Thus, development of new methods 
through  high  throughput  screening  techniques  will 
result  in  the  identification  of  new  generation  mole-
cules targeting TGF and BMP signaling. In this re-
gard,  targeting  the  downstream  regulators  Smads 
might  be  a  more  selective  diminution  of  the  TGF 
signaling. 
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